Shiv Kumar Agarwal
Concepts (276)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 20 | 2024 | 221 | 6.790 |
Why?
| | Percutaneous Coronary Intervention | 14 | 2022 | 307 | 3.080 |
Why?
| | Fractional Flow Reserve, Myocardial | 9 | 2022 | 127 | 2.370 |
Why?
| | Coronary Artery Disease | 9 | 2022 | 294 | 2.050 |
Why?
| | Diabetes Mellitus | 6 | 2024 | 316 | 1.650 |
Why?
| | Coronary Stenosis | 3 | 2021 | 98 | 1.290 |
Why?
| | Blood Glucose | 12 | 2024 | 473 | 1.280 |
Why?
| | Blood Glucose Self-Monitoring | 8 | 2024 | 47 | 1.260 |
Why?
| | Hospitalization | 7 | 2024 | 736 | 1.020 |
Why?
| | Coronary Occlusion | 3 | 2021 | 79 | 0.950 |
Why?
| | Coronary Angiography | 11 | 2022 | 367 | 0.940 |
Why?
| | Humans | 66 | 2024 | 52483 | 0.910 |
Why?
| | Treatment Outcome | 20 | 2022 | 5422 | 0.810 |
Why?
| | Ecosystem | 1 | 2023 | 96 | 0.770 |
Why?
| | Technology | 4 | 2022 | 23 | 0.770 |
Why?
| | Racism | 1 | 2023 | 61 | 0.750 |
Why?
| | Aneurysm, False | 1 | 2020 | 42 | 0.670 |
Why?
| | Transition to Adult Care | 2 | 2016 | 18 | 0.650 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2024 | 560 | 0.640 |
Why?
| | Young Adult | 14 | 2024 | 4329 | 0.630 |
Why?
| | Skin | 2 | 2019 | 422 | 0.610 |
Why?
| | Hemodynamics | 2 | 2017 | 263 | 0.610 |
Why?
| | Myocardial Ischemia | 2 | 2016 | 121 | 0.580 |
Why?
| | Coronary Vessels | 5 | 2021 | 166 | 0.570 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 227 | 0.530 |
Why?
| | Glucocorticoids | 1 | 2019 | 235 | 0.530 |
Why?
| | Male | 37 | 2024 | 26761 | 0.530 |
Why?
| | Renal Dialysis | 6 | 2018 | 179 | 0.530 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 595 | 0.510 |
Why?
| | Phospholipases A1 | 1 | 2015 | 1 | 0.500 |
Why?
| | Cholera | 1 | 2015 | 2 | 0.500 |
Why?
| | Vibrio cholerae | 1 | 2015 | 2 | 0.500 |
Why?
| | Angioplasty, Balloon | 2 | 2019 | 68 | 0.500 |
Why?
| | Cardiac Catheterization | 4 | 2020 | 232 | 0.500 |
Why?
| | Phosphatidylinositol Phosphates | 1 | 2015 | 17 | 0.490 |
Why?
| | Diabetes Complications | 3 | 2021 | 122 | 0.490 |
Why?
| | Endosomes | 1 | 2015 | 36 | 0.490 |
Why?
| | Acute Kidney Injury | 5 | 2018 | 319 | 0.490 |
Why?
| | Bacterial Toxins | 1 | 2015 | 51 | 0.480 |
Why?
| | Postpericardiotomy Syndrome | 1 | 2015 | 4 | 0.480 |
Why?
| | Autophagy | 2 | 2021 | 193 | 0.470 |
Why?
| | Pericardiectomy | 1 | 2015 | 6 | 0.470 |
Why?
| | Program Evaluation | 1 | 2016 | 353 | 0.470 |
Why?
| | Colchicine | 1 | 2015 | 24 | 0.470 |
Why?
| | Pericarditis | 1 | 2015 | 20 | 0.460 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2015 | 33 | 0.460 |
Why?
| | Middle Aged | 25 | 2024 | 13028 | 0.460 |
Why?
| | Secondary Prevention | 1 | 2015 | 84 | 0.460 |
Why?
| | Female | 30 | 2024 | 28171 | 0.440 |
Why?
| | Hypertension | 3 | 2020 | 565 | 0.440 |
Why?
| | Awareness | 1 | 2014 | 27 | 0.440 |
Why?
| | Emigrants and Immigrants | 1 | 2014 | 37 | 0.420 |
Why?
| | Stents | 5 | 2022 | 351 | 0.420 |
Why?
| | Aged | 21 | 2024 | 10121 | 0.380 |
Why?
| | United States | 13 | 2024 | 5192 | 0.370 |
Why?
| | Adult | 17 | 2024 | 14161 | 0.360 |
Why?
| | Quality Improvement | 2 | 2024 | 226 | 0.360 |
Why?
| | Hyperglycemia | 2 | 2022 | 88 | 0.350 |
Why?
| | Healthcare Disparities | 3 | 2024 | 299 | 0.350 |
Why?
| | Retrospective Studies | 13 | 2024 | 6607 | 0.330 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 509 | 0.320 |
Why?
| | Prostatic Neoplasms | 2 | 2023 | 398 | 0.320 |
Why?
| | Predictive Value of Tests | 8 | 2022 | 944 | 0.320 |
Why?
| | Adolescent | 11 | 2024 | 6739 | 0.320 |
Why?
| | Risk Factors | 12 | 2023 | 3889 | 0.310 |
Why?
| | Time Factors | 8 | 2020 | 2968 | 0.310 |
Why?
| | Receptors, Glucocorticoid | 2 | 2019 | 34 | 0.300 |
Why?
| | Drug-Eluting Stents | 3 | 2018 | 94 | 0.290 |
Why?
| | Insulin | 2 | 2021 | 479 | 0.260 |
Why?
| | Algorithms | 3 | 2021 | 672 | 0.260 |
Why?
| | Insulin Infusion Systems | 3 | 2021 | 15 | 0.260 |
Why?
| | Angioplasty, Balloon, Coronary | 2 | 2018 | 136 | 0.250 |
Why?
| | Hospital Mortality | 5 | 2022 | 435 | 0.230 |
Why?
| | Transcription Factors | 2 | 2019 | 566 | 0.230 |
Why?
| | Longitudinal Studies | 2 | 2024 | 747 | 0.220 |
Why?
| | Receptors, CXCR | 1 | 2023 | 1 | 0.210 |
Why?
| | Prospective Studies | 4 | 2024 | 2481 | 0.210 |
Why?
| | Receptors, Androgen | 1 | 2023 | 46 | 0.200 |
Why?
| | Odds Ratio | 4 | 2017 | 558 | 0.200 |
Why?
| | Social Environment | 1 | 2023 | 81 | 0.200 |
Why?
| | Endocrinology | 1 | 2022 | 11 | 0.200 |
Why?
| | Insurance | 1 | 2022 | 10 | 0.200 |
Why?
| | Heart Failure | 2 | 2018 | 565 | 0.190 |
Why?
| | Atrophy | 2 | 2019 | 45 | 0.190 |
Why?
| | Hypotension, Controlled | 1 | 2021 | 3 | 0.190 |
Why?
| | Keratinocytes | 2 | 2019 | 93 | 0.180 |
Why?
| | Hypoglycemia | 2 | 2023 | 59 | 0.180 |
Why?
| | R-SNARE Proteins | 1 | 2021 | 9 | 0.180 |
Why?
| | Remote Sensing Technology | 1 | 2021 | 2 | 0.180 |
Why?
| | Multivariate Analysis | 3 | 2017 | 591 | 0.180 |
Why?
| | Phosphorylation | 2 | 2021 | 528 | 0.180 |
Why?
| | Conserved Sequence | 1 | 2021 | 53 | 0.180 |
Why?
| | Minority Groups | 1 | 2022 | 135 | 0.180 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 483 | 0.170 |
Why?
| | Aortic Valve Stenosis | 1 | 2022 | 76 | 0.170 |
Why?
| | Heart Valve Prosthesis | 1 | 2022 | 86 | 0.170 |
Why?
| | Protein Conformation | 1 | 2021 | 176 | 0.170 |
Why?
| | Aorta | 2 | 2019 | 165 | 0.170 |
Why?
| | Pericardium | 1 | 2020 | 29 | 0.170 |
Why?
| | Telemedicine | 2 | 2024 | 494 | 0.170 |
Why?
| | Reproducibility of Results | 2 | 2021 | 1229 | 0.170 |
Why?
| | Prevalence | 1 | 2023 | 1006 | 0.160 |
Why?
| | Models, Molecular | 1 | 2021 | 348 | 0.160 |
Why?
| | Heart-Assist Devices | 2 | 2018 | 163 | 0.160 |
Why?
| | Enbucrilate | 1 | 2019 | 6 | 0.160 |
Why?
| | Area Under Curve | 2 | 2016 | 180 | 0.160 |
Why?
| | Tissue Adhesives | 1 | 2019 | 13 | 0.160 |
Why?
| | Heart Injuries | 1 | 2019 | 16 | 0.160 |
Why?
| | Arterial Pressure | 1 | 2019 | 45 | 0.160 |
Why?
| | Follow-Up Studies | 4 | 2018 | 2279 | 0.160 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2019 | 7 | 0.160 |
Why?
| | Prognosis | 4 | 2018 | 2099 | 0.160 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2019 | 80 | 0.150 |
Why?
| | Critical Illness | 1 | 2021 | 317 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2019 | 169 | 0.150 |
Why?
| | Exercise Test | 2 | 2016 | 141 | 0.140 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2019 | 151 | 0.140 |
Why?
| | Sirolimus | 1 | 2018 | 65 | 0.140 |
Why?
| | Glucagon | 1 | 2017 | 24 | 0.140 |
Why?
| | Hormones | 1 | 2017 | 59 | 0.140 |
Why?
| | Population Surveillance | 1 | 2018 | 165 | 0.140 |
Why?
| | Atrial Fibrillation | 2 | 2016 | 200 | 0.140 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 178 | 0.130 |
Why?
| | Cell Survival | 1 | 2019 | 612 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.130 |
Why?
| | Hyperemia | 1 | 2016 | 17 | 0.130 |
Why?
| | Patient Discharge | 2 | 2018 | 330 | 0.130 |
Why?
| | Lower Extremity | 1 | 2017 | 100 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2017 | 1026 | 0.130 |
Why?
| | Angina, Stable | 1 | 2016 | 7 | 0.130 |
Why?
| | Recurrence | 2 | 2016 | 672 | 0.130 |
Why?
| | Angina, Unstable | 1 | 2016 | 24 | 0.130 |
Why?
| | Peripheral Arterial Disease | 1 | 2017 | 75 | 0.130 |
Why?
| | Incidence | 5 | 2018 | 1062 | 0.130 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 1884 | 0.130 |
Why?
| | Adenosine | 1 | 2016 | 71 | 0.130 |
Why?
| | Vasodilator Agents | 1 | 2016 | 96 | 0.130 |
Why?
| | Transcriptome | 1 | 2019 | 370 | 0.130 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 172 | 0.130 |
Why?
| | Chest Pain | 1 | 2016 | 57 | 0.120 |
Why?
| | Patient Readmission | 1 | 2018 | 246 | 0.120 |
Why?
| | Vascular Surgical Procedures | 1 | 2017 | 166 | 0.120 |
Why?
| | Hypoglycemic Agents | 1 | 2017 | 211 | 0.120 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 210 | 0.120 |
Why?
| | Acute Coronary Syndrome | 1 | 2016 | 80 | 0.120 |
Why?
| | Cells, Cultured | 1 | 2019 | 1567 | 0.120 |
Why?
| | Child | 3 | 2024 | 7248 | 0.120 |
Why?
| | Constriction, Pathologic | 1 | 2015 | 91 | 0.120 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 242 | 0.120 |
Why?
| | Protein Transport | 1 | 2015 | 180 | 0.120 |
Why?
| | Tubulin Modulators | 1 | 2015 | 27 | 0.120 |
Why?
| | Vascular Patency | 1 | 2015 | 82 | 0.120 |
Why?
| | Endovascular Procedures | 1 | 2017 | 178 | 0.120 |
Why?
| | Serositis | 1 | 2014 | 1 | 0.120 |
Why?
| | Extracellular Matrix Proteins | 1 | 2015 | 69 | 0.120 |
Why?
| | Cerebral Hemorrhage | 1 | 2015 | 97 | 0.110 |
Why?
| | Tissue Engineering | 1 | 2015 | 74 | 0.110 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 144 | 0.110 |
Why?
| | Brain Ischemia | 1 | 2015 | 161 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 166 | 0.110 |
Why?
| | Arkansas | 2 | 2016 | 2028 | 0.100 |
Why?
| | Lithium | 1 | 2013 | 35 | 0.100 |
Why?
| | Calcium | 1 | 2015 | 376 | 0.100 |
Why?
| | Databases, Factual | 4 | 2017 | 706 | 0.100 |
Why?
| | Bradycardia | 1 | 2013 | 38 | 0.100 |
Why?
| | Tumor Microenvironment | 1 | 2015 | 256 | 0.100 |
Why?
| | Echocardiography, Stress | 1 | 2012 | 9 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 236 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 399 | 0.100 |
Why?
| | Clostridium septicum | 1 | 2012 | 2 | 0.100 |
Why?
| | Aortitis | 1 | 2012 | 4 | 0.100 |
Why?
| | Dyspnea | 1 | 2012 | 78 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2014 | 284 | 0.100 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2016 | 266 | 0.090 |
Why?
| | Plaque, Atherosclerotic | 1 | 2012 | 44 | 0.090 |
Why?
| | Stroke Volume | 1 | 2012 | 155 | 0.090 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2016 | 289 | 0.090 |
Why?
| | Mice | 2 | 2019 | 5949 | 0.090 |
Why?
| | Clostridium Infections | 1 | 2012 | 55 | 0.090 |
Why?
| | HIV Infections | 1 | 2015 | 389 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2018 | 1068 | 0.090 |
Why?
| | Clinical Competence | 1 | 2014 | 406 | 0.090 |
Why?
| | Stroke | 1 | 2015 | 512 | 0.080 |
Why?
| | Logistic Models | 3 | 2017 | 925 | 0.080 |
Why?
| | Hospitals | 2 | 2022 | 182 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 1678 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 1165 | 0.080 |
Why?
| | Cell Proliferation | 2 | 2023 | 1023 | 0.080 |
Why?
| | Cell Line, Tumor | 2 | 2023 | 1470 | 0.080 |
Why?
| | Registries | 2 | 2021 | 581 | 0.070 |
Why?
| | Risk Assessment | 2 | 2023 | 1327 | 0.070 |
Why?
| | Animals | 2 | 2019 | 13505 | 0.070 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 288 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 1222 | 0.060 |
Why?
| | Length of Stay | 2 | 2018 | 663 | 0.060 |
Why?
| | Comorbidity | 2 | 2016 | 625 | 0.060 |
Why?
| | Acyltransferases | 1 | 2023 | 25 | 0.050 |
Why?
| | Sepsis | 2 | 2016 | 239 | 0.050 |
Why?
| | Androgens | 1 | 2023 | 70 | 0.050 |
Why?
| | Consensus | 1 | 2022 | 181 | 0.050 |
Why?
| | Caregivers | 1 | 2024 | 240 | 0.050 |
Why?
| | Pilot Projects | 1 | 2024 | 721 | 0.050 |
Why?
| | Societies, Medical | 1 | 2022 | 200 | 0.050 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 21 | 0.050 |
Why?
| | Equipment and Supplies | 1 | 2021 | 16 | 0.040 |
Why?
| | Parity | 1 | 2020 | 52 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2024 | 321 | 0.040 |
Why?
| | Aortic Valve | 1 | 2022 | 123 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2021 | 93 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 8 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2023 | 323 | 0.040 |
Why?
| | Ischemia | 1 | 2021 | 150 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2021 | 65 | 0.040 |
Why?
| | Calibration | 1 | 2020 | 57 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2020 | 38 | 0.040 |
Why?
| | Cell Membrane | 1 | 2021 | 245 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 98 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 404 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2021 | 3392 | 0.040 |
Why?
| | Sex Factors | 1 | 2022 | 727 | 0.040 |
Why?
| | Materials Testing | 1 | 2019 | 58 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2021 | 313 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 243 | 0.040 |
Why?
| | Protein Binding | 1 | 2021 | 667 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2021 | 215 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2023 | 857 | 0.040 |
Why?
| | Attitude of Health Personnel | 1 | 2022 | 360 | 0.040 |
Why?
| | Catheterization | 1 | 2019 | 96 | 0.040 |
Why?
| | Amino Acids | 1 | 2021 | 377 | 0.040 |
Why?
| | Inpatients | 1 | 2020 | 205 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2020 | 406 | 0.040 |
Why?
| | Steroids | 1 | 2018 | 59 | 0.040 |
Why?
| | Limb Salvage | 1 | 2017 | 40 | 0.040 |
Why?
| | Body Weight | 1 | 2020 | 523 | 0.040 |
Why?
| | Electronic Health Records | 1 | 2020 | 268 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 1542 | 0.030 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2018 | 108 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 256 | 0.030 |
Why?
| | Hospital Costs | 1 | 2017 | 72 | 0.030 |
Why?
| | Population Growth | 1 | 2016 | 2 | 0.030 |
Why?
| | Liver Failure | 1 | 2016 | 22 | 0.030 |
Why?
| | Chronic Disease | 1 | 2019 | 586 | 0.030 |
Why?
| | Phenotype | 1 | 2020 | 789 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2017 | 238 | 0.030 |
Why?
| | Signal Transduction | 1 | 2023 | 1671 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2018 | 243 | 0.030 |
Why?
| | Propensity Score | 1 | 2017 | 154 | 0.030 |
Why?
| | Counseling | 1 | 2016 | 136 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 253 | 0.030 |
Why?
| | Self Care | 1 | 2016 | 138 | 0.030 |
Why?
| | Long-Term Care | 1 | 2015 | 51 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 443 | 0.030 |
Why?
| | Survival Rate | 1 | 2018 | 945 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 585 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2016 | 120 | 0.030 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2015 | 45 | 0.030 |
Why?
| | Incidental Findings | 1 | 2015 | 43 | 0.030 |
Why?
| | Arthritis, Psoriatic | 1 | 2014 | 9 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2015 | 67 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 180 | 0.030 |
Why?
| | New York City | 1 | 2014 | 25 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2016 | 308 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2015 | 240 | 0.030 |
Why?
| | Internal Medicine | 1 | 2014 | 19 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 54 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2015 | 554 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2015 | 251 | 0.030 |
Why?
| | Survival Analysis | 1 | 2015 | 673 | 0.030 |
Why?
| | Pregnancy | 1 | 2020 | 2680 | 0.030 |
Why?
| | Myocardial Infarction | 1 | 2017 | 412 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2018 | 1478 | 0.030 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 187 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2012 | 284 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1105 | 0.020 |
Why?
| | Internship and Residency | 1 | 2014 | 448 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 807 | 0.020 |
Why?
|
|
Agarwal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|